Sogroya
Chemical Name | somapacitan-beco |
Dosage Form | Injection (subcutaneous; 10 mg/1.5 mL, 6.7 mg/mL) |
Drug Class | Hormones |
System | Endocrine |
Company | Novo Nordisk Inc. |
Approval Year | 2020 |
Indication
- For replacement of growth hormone in adults with growth hormone deficiency (GHD).